Clinical proton MR spectroscopy of neurodegenerative disease in childhood

A. A. Tzika, W. S. Ball, D. B. Vigneron, R. S. Dunn, D. R. Kirks, R. A. Zimmerman, J. Valk, Z. Wang

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

PURPOSE: To determine the contribution of MR spectroscopy in the assessment of childhood neurodegenerative disease. METHODS: Fifty-one subjects (7 weeks to 17 years of age), 22 with either hereditary (n = 16) or acquired (n = 6) neurodegenerative disorders and 29 age-matched control subjects, were studied with combined proton MR spectroscopy and MR imaging. Single-voxel (2.0-8.0 cc) MR spectra were acquired at 1.5 T, with either short-echo-stimulated echoes and/or long-echo spin echoes. RESULTS: MR spectra exhibited signals from n-acetyl-, creatine-, and choline-containing compounds, neurotransmitters (glutamate), intracellular mediators (inositols), and glycolytic products (lactate). Abnormal MR spectra in neurodegenerative disorders reflected: demyelination, neuronal loss, and gliosis (increased mobile lipid presence and reduction of n-acetylaspartate to choline); metabolic acidosis (lactate accumulation); and neurotransmitter neurotoxicity (increased glutamate, glutamine, and inositols). CONCLUSION: Proton MR spectroscopy may complement MR imaging in diagnostic assessment and therapeutic monitoring of neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)1267-1284
Number of pages18
JournalAmerican Journal of Neuroradiology
Volume14
Issue number6
StatePublished - 1993

Fingerprint

Neurodegenerative Diseases
Protons
Magnetic Resonance Spectroscopy
Inositol
Choline
Neurotransmitter Agents
Glutamic Acid
Lactic Acid
Gliosis
Creatine
Demyelinating Diseases
Diagnostic Imaging
Acidosis
Glutamine
Lipids
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Tzika, A. A., Ball, W. S., Vigneron, D. B., Dunn, R. S., Kirks, D. R., Zimmerman, R. A., ... Wang, Z. (1993). Clinical proton MR spectroscopy of neurodegenerative disease in childhood. American Journal of Neuroradiology, 14(6), 1267-1284.

Clinical proton MR spectroscopy of neurodegenerative disease in childhood. / Tzika, A. A.; Ball, W. S.; Vigneron, D. B.; Dunn, R. S.; Kirks, D. R.; Zimmerman, R. A.; Valk, J.; Wang, Z.

In: American Journal of Neuroradiology, Vol. 14, No. 6, 1993, p. 1267-1284.

Research output: Contribution to journalArticle

Tzika, AA, Ball, WS, Vigneron, DB, Dunn, RS, Kirks, DR, Zimmerman, RA, Valk, J & Wang, Z 1993, 'Clinical proton MR spectroscopy of neurodegenerative disease in childhood', American Journal of Neuroradiology, vol. 14, no. 6, pp. 1267-1284.
Tzika AA, Ball WS, Vigneron DB, Dunn RS, Kirks DR, Zimmerman RA et al. Clinical proton MR spectroscopy of neurodegenerative disease in childhood. American Journal of Neuroradiology. 1993;14(6):1267-1284.
Tzika, A. A. ; Ball, W. S. ; Vigneron, D. B. ; Dunn, R. S. ; Kirks, D. R. ; Zimmerman, R. A. ; Valk, J. ; Wang, Z. / Clinical proton MR spectroscopy of neurodegenerative disease in childhood. In: American Journal of Neuroradiology. 1993 ; Vol. 14, No. 6. pp. 1267-1284.
@article{fd48590837d84b699eb1b721c667488c,
title = "Clinical proton MR spectroscopy of neurodegenerative disease in childhood",
abstract = "PURPOSE: To determine the contribution of MR spectroscopy in the assessment of childhood neurodegenerative disease. METHODS: Fifty-one subjects (7 weeks to 17 years of age), 22 with either hereditary (n = 16) or acquired (n = 6) neurodegenerative disorders and 29 age-matched control subjects, were studied with combined proton MR spectroscopy and MR imaging. Single-voxel (2.0-8.0 cc) MR spectra were acquired at 1.5 T, with either short-echo-stimulated echoes and/or long-echo spin echoes. RESULTS: MR spectra exhibited signals from n-acetyl-, creatine-, and choline-containing compounds, neurotransmitters (glutamate), intracellular mediators (inositols), and glycolytic products (lactate). Abnormal MR spectra in neurodegenerative disorders reflected: demyelination, neuronal loss, and gliosis (increased mobile lipid presence and reduction of n-acetylaspartate to choline); metabolic acidosis (lactate accumulation); and neurotransmitter neurotoxicity (increased glutamate, glutamine, and inositols). CONCLUSION: Proton MR spectroscopy may complement MR imaging in diagnostic assessment and therapeutic monitoring of neurodegenerative disorders.",
author = "Tzika, {A. A.} and Ball, {W. S.} and Vigneron, {D. B.} and Dunn, {R. S.} and Kirks, {D. R.} and Zimmerman, {R. A.} and J. Valk and Z. Wang",
year = "1993",
language = "English (US)",
volume = "14",
pages = "1267--1284",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "6",

}

TY - JOUR

T1 - Clinical proton MR spectroscopy of neurodegenerative disease in childhood

AU - Tzika, A. A.

AU - Ball, W. S.

AU - Vigneron, D. B.

AU - Dunn, R. S.

AU - Kirks, D. R.

AU - Zimmerman, R. A.

AU - Valk, J.

AU - Wang, Z.

PY - 1993

Y1 - 1993

N2 - PURPOSE: To determine the contribution of MR spectroscopy in the assessment of childhood neurodegenerative disease. METHODS: Fifty-one subjects (7 weeks to 17 years of age), 22 with either hereditary (n = 16) or acquired (n = 6) neurodegenerative disorders and 29 age-matched control subjects, were studied with combined proton MR spectroscopy and MR imaging. Single-voxel (2.0-8.0 cc) MR spectra were acquired at 1.5 T, with either short-echo-stimulated echoes and/or long-echo spin echoes. RESULTS: MR spectra exhibited signals from n-acetyl-, creatine-, and choline-containing compounds, neurotransmitters (glutamate), intracellular mediators (inositols), and glycolytic products (lactate). Abnormal MR spectra in neurodegenerative disorders reflected: demyelination, neuronal loss, and gliosis (increased mobile lipid presence and reduction of n-acetylaspartate to choline); metabolic acidosis (lactate accumulation); and neurotransmitter neurotoxicity (increased glutamate, glutamine, and inositols). CONCLUSION: Proton MR spectroscopy may complement MR imaging in diagnostic assessment and therapeutic monitoring of neurodegenerative disorders.

AB - PURPOSE: To determine the contribution of MR spectroscopy in the assessment of childhood neurodegenerative disease. METHODS: Fifty-one subjects (7 weeks to 17 years of age), 22 with either hereditary (n = 16) or acquired (n = 6) neurodegenerative disorders and 29 age-matched control subjects, were studied with combined proton MR spectroscopy and MR imaging. Single-voxel (2.0-8.0 cc) MR spectra were acquired at 1.5 T, with either short-echo-stimulated echoes and/or long-echo spin echoes. RESULTS: MR spectra exhibited signals from n-acetyl-, creatine-, and choline-containing compounds, neurotransmitters (glutamate), intracellular mediators (inositols), and glycolytic products (lactate). Abnormal MR spectra in neurodegenerative disorders reflected: demyelination, neuronal loss, and gliosis (increased mobile lipid presence and reduction of n-acetylaspartate to choline); metabolic acidosis (lactate accumulation); and neurotransmitter neurotoxicity (increased glutamate, glutamine, and inositols). CONCLUSION: Proton MR spectroscopy may complement MR imaging in diagnostic assessment and therapeutic monitoring of neurodegenerative disorders.

UR - http://www.scopus.com/inward/record.url?scp=0027428591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027428591&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1267

EP - 1284

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 6

ER -